You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

445 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
Jun 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated MSI-H/dMMR Advanced Endometrial Cancer
Jul 2023
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Feb 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jun 2022
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced Esophageal and Esophagogastric Junction Carcinoma
Jan 2023
Regimen
Intent: Adjuvant
Jan 2023

Pages